Stocks to Watch: Intuit, Spyre Therapeutics, Zoom Communications, nCino
Intuit forecasted slower sales growth and shares fell 9.8% after-hours. Spyre Therapeutics abandoned a drug candidate after trial results missed targets, dropping 11%. Zoom Communications' Q3 EPS guidance missed estimates, shares down 3.9%. nCino's Q3 revenue projection fell short of expectations, stock down 5.6%.
How this was made
The 30-second read
Why it matters
Each company disclosed fresh guidance or trial outcomes that moved their shares significantly in after‑hours trading.
Market read
New guidance and trial news drive immediate price moves, offering short‑term trading opportunities.
What to watch
Potential cost‑saving initiatives or product launches not disclosed may mitigate the downside.
Background
The article aggregates recent earnings‑related guidance and trial updates for four publicly traded companies.
Ticker impact
Intuit warned sales growth will slow and its desktop business will decline, causing a 9.8% after‑hours drop.
Further downside pressure if guidance remains below expectations.
Guidance is a primary disclosure with a sizable move; traders may consider short positions or reduce exposure.
Spyre Therapeutics said it will not prioritize a rheumatoid‑arthritis monotherapy after a trial missed internal targets, sending the stock down 11%.
Potential further decline if additional data are negative.
First report of trial decision; investors may re‑price the pipeline.
Zoom Communications issued Q3 adjusted EPS guidance that missed Wall Street expectations, resulting in a 3.9% drop.
Likely continued weakness until next earnings update.
Guidance is new information; traders may adjust positions accordingly.
nCino projected Q3 revenue below analyst expectations, causing a 5.6% decline.
Further downside possible if guidance is not revised upward.
First disclosure of revenue range; market may react negatively.
Market effects
Software and fintech earnings guidance may weigh on broader tech and SaaS valuations.
U.S. equity markets may see modest pullback in the tech sector.
Limited to U.S. listed companies; no immediate global macro impact.
Counterpoint
If guidance is overly conservative, the stocks could rebound on a short‑cover rally.
Key entities
- CompanyIntuit
Financial software provider (INTU).
- CompanySpyre Therapeutics
Biotech firm (SPRO).
- CompanyZoom Communications
Video‑conferencing provider (ZM).
- CompanynCino
Cloud banking platform (NCNO).
